Demystifying MRD with BLOODPAC: Navigating Clinical and Technical Pathways for Comprehensive Cancer Monitoring

Date: Wednesday, November 12, 2025
Time: 4:00 – 4:50 PM
Location: Boston, Massachusetts
Event: Association for Molecular Pathology (AMP) 2025 Annual Meeting

BLOODPAC Executive Director Lauren Leiman will moderate a panel discussion titled “Demystifying MRD with BLOODPAC: Navigating Clinical and Technical Pathways for Comprehensive Cancer Monitoring.”

This session will bring together leaders from academia, industry, and collaborative consortia to address the evolving landscape of Minimal Residual Disease (MRD) testing in cancer care. Panelists will discuss emerging best practices, indication-specific requirements, and the growing value of whole genome sequencing (WGS)-based MRD approaches. The conversation will also explore the ongoing debate between tissue-informed and tissue-agnostic strategies.

Panelists:

• Traci Pawlowski, PhD – Vice President, Head Clinical Solutions, Illumina

• Aparna R. Parikh, MD – Associate Professor of Medicine, Harvard Medical School

• Jonathan Beer – Senior Director, Precision Medicine Lead, Bristol Myers Squibb

• Jim Godsey, PhD – Scientific Co-Chair, BLOODPAC

Attendees will gain valuable insights into optimizing MRD testing workflows to enhance patient outcomes while aligning with regulatory, scientific, and clinical standards.